"I don't smoke, so I can't get lung cancer."
It is one of the most common misconceptions about lung cancer, and one that specialists say continues to delay diagnosis. While smoking remains the leading cause of lung cancer worldwide, thousands of people who have never smoked are diagnosed every year. For many of them, symptoms are initially mistaken for asthma, allergies, or a lingering chest infection.
According to the World Health Organization (WHO), lung cancer was responsible for an estimated 1.8 million deaths worldwide in 2022, making it the leading cause of cancer-related deaths globally.¹ Although smoking remains the leading cause of lung cancer, epidemiological studies estimate that approximately 10 to 20 percent of lung cancers occur in people who have never smoked, with the proportion varying across countries and populations.²
This misconception carries real consequences. Many people who have never smoked do not consider themselves at risk, and healthcare professionals may initially attribute persistent cough, breathlessness, or fatigue to more common conditions such as asthma, respiratory infections, or allergies. As a result, diagnosis may be delayed until the disease has progressed.
Recognized each year on August 1, World Lung Cancer Day aims to improve awareness of lung cancer, encourage earlier diagnosis, reduce stigma, and highlight advances in treatment. This year's observance is also an opportunity to remind the public that lung cancer is not exclusively a smoker's disease.
Although researchers continue to investigate why lung cancer develops in people who have never smoked, evidence shows that multiple factors may contribute, including secondhand smoke, air pollution, occupational exposures, genetic susceptibility, previous lung diseases, and acquired genetic mutations within tumor cells.²⁻⁶ Some of these factors are well established, while others remain areas of active research.
This feature examines what is currently known about lung cancer in never-smokers, who may be at increased risk, the symptoms that should never be ignored, and why advances in diagnosis are helping identify the disease earlier than ever before. It also includes original insights from pulmonologists and thoracic surgeons who diagnose and treat lung cancer in clinical practice.
"Lung cancer in never-smokers" generally refers to lung cancer occurring in individuals who have smoked fewer than 100 cigarettes during their lifetime, a definition commonly used in research.²
Although these patients have never actively smoked, lung cancer remains an important cause of cancer-related illness and death worldwide.
Never-smoker lung cancer also differs from smoking-related lung cancer in several important ways.
Compared with smokers, never-smokers are more likely to:
Develop lung adenocarcinoma, the most common subtype of non-small cell lung cancer.
Be diagnosed at a younger age, although it can occur at any age.
Be women, particularly in Asian populations.
Have tumors driven by specific genetic alterations such as EGFR or ALK, which may respond to targeted therapies.³⁻⁵
These differences have changed how clinicians evaluate, diagnose, and treat lung cancer today.
MedBound Times connected with thoracic surgical oncologist Dr. Anjali Singh, MCh Surgical Oncology, who specializes in minimally invasive thoracic surgery, including Uniportal Video-Assisted Thoracoscopic Surgery (Uniportal VATS), says the pattern of patients seen in clinical practice is changing.
"While smoking remains the strongest risk factor for lung cancer, we are increasingly diagnosing lung cancer in people who have never smoked, including younger adults. Many of these patients present with lung adenocarcinoma, which is often associated with specific genetic alterations such as EGFR mutations or ALK rearrangements. This changing pattern reminds us that lung cancer is no longer exclusively a smoker's disease."
Her observations reflect trends reported in epidemiological studies, particularly across East and South Asia, where lung adenocarcinoma among never-smokers has become an important area of research.³⁻⁵
Unlike smoking-related lung cancer, which has a clearly established primary cause, lung cancer in never-smokers usually develops through a combination of environmental exposures, inherited susceptibility, and biological changes that accumulate over time.
For many patients, no single cause can be identified.
Instead, experts believe several factors may interact to increase risk.
Unlike smoking-related lung cancer, which has a clearly established primary cause, lung cancer in never-smokers usually develops through a combination of environmental exposures, inherited susceptibility, and biological changes that accumulate over time.
For many patients, no single cause can be identified.
Instead, experts believe several factors may interact to increase risk.
| Risk Factor | Current Level of Evidence |
|---|---|
| Cigarette smoking | Established cause |
| Secondhand smoke | Established cause |
| Outdoor air pollution | Established cause |
| Household biomass smoke | Established cause |
| Occupational carcinogens (asbestos, silica, diesel exhaust, arsenic) | Established cause |
| Previous lung diseases (e.g., pulmonary fibrosis, tuberculosis) | Associated risk factor |
| Family history and genetic susceptibility | Associated risk factor |
| Driver mutations (EGFR, ALK, ROS1, RET, MET, HER2) | Tumor biology rather than a direct exposure risk factor |
| Vaping | Long-term lung cancer risk remains under investigation |
Outdoor air pollution has become one of the most important environmental risk factors for lung cancer.
The International Agency for Research on Cancer (IARC) has classified both outdoor air pollution and particulate matter as Group 1 carcinogens, meaning there is sufficient evidence that they cause cancer in humans.⁶
Fine particulate matter (PM2.5), produced by vehicle emissions, industrial activity, construction, and the burning of fossil fuels, can penetrate deep into the lungs and contribute to chronic inflammation and DNA damage over time.
According to the WHO, air pollution contributes to millions of premature deaths every year, including deaths from lung cancer.¹
Although reducing exposure cannot eliminate risk entirely, improving air quality remains an important public health measure.
Not smoking does not necessarily mean avoiding tobacco smoke.
Secondhand smoke contains many of the same carcinogens inhaled directly by smokers. Living with a smoker or being exposed to tobacco smoke at home or in the workplace can increase lung cancer risk over time.¹⁻²
For this reason, smoke-free environments benefit not only smokers who wish to quit but also family members, children, and colleagues who may otherwise experience long-term passive exposure.
In many parts of the world, including rural communities, cooking or heating with biomass fuels such as wood, crop residue, charcoal, or dung in poorly ventilated spaces exposes families to harmful smoke for many years.
Women often experience greater cumulative exposure because they traditionally spend more time cooking in these environments.
According to the WHO, household air pollution remains an important cause of respiratory disease and contributes to lung cancer risk among populations relying on solid fuels.⁷
Certain occupations expose workers to carcinogens that have been linked to lung cancer, even among people who have never smoked.
Examples include:
Asbestos
Silica dust
Diesel exhaust
Arsenic
Chromium compounds
Nickel compounds
The degree of risk depends on the intensity and duration of exposure, workplace safety practices, and whether multiple risk factors coexist.
Dr. Saurabh Goyal, Director, Pulmonary and Critical Care and Sleep Medicine, said to MedBound Times that among never-smokers, those at higher risk include people exposed to secondhand smoke, indoor biomass smoke, occupational carcinogens such as asbestos, silica, diesel exhaust, arsenic, and individuals with previous lung diseases or a family history suggesting inherited susceptibility.
He also points out that many tumors in never-smokers carry driver mutations such as EGFR, ALK, ROS1, RET, MET, or HER2, highlighting the biological differences between smoking-related and never-smoker lung cancers.
One of the biggest differences between lung cancer in smokers and never-smokers lies in tumor biology.
Researchers have found that tumors in never-smokers more commonly contain driver mutations, which are acquired genetic alterations that help cancer cells grow and survive.³⁻⁵
Some of the best-known include:
EGFR
ALK rearrangements
ROS1
RET
MET
HER2
These mutations are not usually inherited from parents. Instead, they develop within the tumor cells during a person's lifetime.
Their discovery has transformed lung cancer treatment because many patients with these mutations can receive targeted therapies, medicines designed to block the abnormal proteins driving cancer growth.
This is one reason obtaining adequate tissue during biopsy has become increasingly important.
MedBound Times also connected with thoracic surgeon Dr. Prriya Eshpuniyani, who performs open, video-assisted thoracoscopic surgery (VATS) and robotic thoracic surgery, says she is seeing more cases among women who have never smoked.
Lung cancer cases are being seen more now in non-smokers, especially middle-aged women. Causes are being attributed to genetic mutations.Dr. Prriya Eshpuniyani
Current research supports that EGFR mutations are substantially more common among Asian patients with lung adenocarcinoma who have never smoked, although reported frequencies vary depending on ethnicity, geography, and study population.³⁻⁵ Rather than representing inherited disease, these mutations usually arise within the cancer itself and can influence treatment decisions.
Dr. Eshpuniyani also notes that younger adults with lung cancer are increasingly being encountered in clinical practice, with factors such as occupational exposures, air pollution, and vaping among the possible contributors currently being investigated.
Importantly, while evidence linking cigarette smoking to lung cancer is overwhelming, research into vaping and long-term lung cancer risk is still evolving. Current evidence is insufficient to conclude that vaping causes lung cancer in the same way as combustible tobacco, but researchers continue to study its long-term health effects.⁸
Scientists still do not know why some never-smokers develop lung cancer while others with similar exposures do not.
Researchers continue to investigate the roles of chronic inflammation, hormonal influences, inherited susceptibility, environmental exposures, and interactions between genes and the environment.²⁻⁵
What is already clear, however, is that never smoking does not eliminate the possibility of developing lung cancer.
That reality makes awareness of symptoms and timely medical evaluation especially important, a topic explored in the next section.
The biggest challenge is that lung cancer is often not suspected in someone who has never smoked.Dr. Vivek Gundappa, Clinical Lead, Pulmonology, Interventions & Lung Transplant, Fortis Hospital, Yeshwanthpur, and Usiru Speciality Clinics
One of the biggest challenges in diagnosing lung cancer in people who have never smoked is that neither patients nor healthcare professionals may initially suspect the disease.
Early symptoms are often vague and can resemble far more common conditions such as viral respiratory infections, asthma, allergies, acid reflux, or bronchitis. As a result, treatment may focus on these conditions first, delaying investigations that could identify lung cancer at an earlier stage. Studies have shown that never-smokers may experience longer diagnostic intervals because their perceived risk is lower than that of smokers.¹⁻³
Speaking to MedBound Times, Dr. Vivek Gundappa, Clinical Lead, Pulmonology, Interventions & Lung Transplant, Fortis Hospital, Yeshwanthpur, and Usiru Speciality Clinics, said:
"The biggest challenge is that lung cancer is often not suspected in someone who has never smoked. Symptoms like cough or breathlessness are easily mistaken for infections or asthma, and early lung cancers can appear as very subtle nodules on scans. Maintaining a high index of suspicion and referring patients early to centers with advanced diagnostic facilities can make a significant difference."
His observation highlights an important clinical message. A persistent symptom deserves evaluation based on its duration and progression, not simply on whether a person has smoked.
Most coughs are not caused by lung cancer. However, symptoms that persist, worsen, or occur together warrant medical assessment.
Common warning signs include:
A cough lasting more than three to four weeks, especially if it does not improve with appropriate treatment, should be evaluated.
Even small streaks of blood in sputum should never be ignored.
Difficulty breathing without a clear explanation may indicate an underlying lung condition requiring further investigation.
Pain that persists, particularly when breathing deeply or coughing, deserves medical attention.
Repeated episodes of pneumonia or bronchitis affecting the same area of the lung may require further imaging.
Persistent hoarseness lasting more than two weeks can occur if a tumor affects the nerve supplying the vocal cords.
Unintentional weight loss, persistent tiredness, and reduced exercise tolerance should not be dismissed without evaluation.
Dr. Saurabh Goyal advises that never-smokers should seek medical evaluation if symptoms such as persistent cough lasting more than three to four weeks, coughing up blood, progressive breathlessness, unexplained weight loss, recurrent localized pneumonia, chest pain, or persistent hoarseness occur.
He adds that the threshold for chest imaging and specialist referral should remain low in these situations, even for people who have never smoked.
Similarly, Dr. Anjali Singh emphasizes:
"Never ignore persistent respiratory symptoms simply because you have never smoked. A persistent cough lasting more than three weeks, coughing up blood, unexplained weight loss, chest pain, or persistent breathlessness should always be evaluated. Early-stage lung cancer is often highly treatable, and timely diagnosis can significantly improve outcomes."
While not every persistent cough is caused by lung cancer, persistent unexplained respiratory symptoms deserve timely medical evaluation.
Screening and diagnosis are not the same.
Current international guidelines recommend annual low-dose computed tomography (LDCT) screening primarily for adults at high risk because of their smoking history, as this approach has been shown to reduce lung cancer mortality in appropriately selected individuals.¹¹⁻¹³
At present, there is insufficient evidence to recommend routine lung cancer screening for the general population of never-smokers. However, this does not mean symptoms should be ignored.
People who develop persistent respiratory symptoms, unexplained weight loss, coughing up blood, or concerning findings on chest imaging should undergo appropriate medical evaluation regardless of whether they have ever smoked.
This distinction is important because screening is intended for people without symptoms, whereas persistent or unexplained symptoms require diagnostic assessment.
There is no single profile for a person with lung cancer who has never smoked. However, research suggests certain groups may have a higher risk.
These include:
Women, particularly those diagnosed with lung adenocarcinoma
People with prolonged exposure to secondhand smoke
Individuals exposed to indoor biomass smoke from cooking or heating
Workers exposed to asbestos, silica, diesel exhaust, arsenic, or other occupational carcinogens
People with previous lung diseases such as pulmonary fibrosis or tuberculosis
Individuals with certain inherited susceptibilities or a family history of lung cancer
People living in areas with high levels of air pollution
Risk does not mean certainty. Many people with one or more of these factors will never develop lung cancer, while others diagnosed with lung cancer may have no identifiable risk factor.
Among people who have never smoked, adenocarcinoma is the most frequently diagnosed subtype of lung cancer.³
Unlike squamous cell carcinoma, which has a stronger association with tobacco smoking, adenocarcinoma often develops in the outer regions of the lungs.
Because these tumors may initially grow away from the major airways, they can produce few symptoms during the early stages. Some are discovered incidentally during CT scans performed for unrelated reasons.
The presence of driver mutations such as EGFR and ALK has also changed treatment for many patients. Instead of relying solely on chemotherapy, eligible patients may receive targeted therapies designed to block the abnormal proteins driving cancer growth. Current international guidelines recommend molecular testing for advanced non-small cell lung cancers because identifying these mutations can directly influence treatment decisions.⁸⁻¹⁰
Although awareness remains essential, advances in diagnostic technology are also helping clinicians detect lung cancer more accurately.
Modern approaches allow doctors to reach small lung nodules that were previously difficult to biopsy while obtaining sufficient tissue for detailed molecular analysis.
"Many never-smokers develop small peripheral lung nodules that are difficult to reach with conventional bronchoscopy. Advanced navigation systems, robotic bronchoscopy, and EBUS allow us to safely access these lesions, obtain accurate tissue samples, and stage the disease in the same sitting. Most importantly, they provide enough tissue for molecular testing, which is essential because many never-smokers have targetable mutations that can be treated with precision therapies." says Dr. Vivek Gundappa.
Molecular testing identifies genetic alterations such as EGFR and ALK that can determine whether a patient is eligible for targeted therapies, making adequate tissue sampling increasingly important in modern lung cancer care.
These technologies do not replace clinical judgement or imaging but improve the ability to obtain a diagnosis while minimizing the need for more invasive procedures.
Dr. Saurabh Goyal similarly notes that techniques such as virtual bronchoscopic navigation, electromagnetic navigation bronchoscopy, robotic bronchoscopy, and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) have improved access to small peripheral lung nodules and mediastinal lymph nodes.
According to him, these advances have:
Improved diagnostic yield for small lung nodules.
Reduced the need for more invasive surgical diagnostic procedures in selected patients.
Enabled better tissue sampling for comprehensive molecular profiling.
Supported earlier diagnosis and more personalized treatment planning.
Looking ahead, Dr. Gundappa believes that artificial intelligence-assisted CT analysis, advanced robotic bronchoscopy, real-time imaging, and liquid biopsy represent promising areas of research that may further improve early detection. However, while these technologies are advancing rapidly, several remain under evaluation and are not yet standard screening tools for the general population.
Fact: Smoking remains the leading cause of lung cancer, but people who have never smoked can also develop the disease.
Thoracic surgeon Dr. Prriya Eshpuniyani says this is the misconception she most wants the public to abandon.
"If I don't smoke, I can't get lung cancer. That is the biggest misconception. Even if a non-smoker develops symptoms, they should get themselves checked rather than assuming they cannot have lung cancer."
Fact: Lung cancer becomes more common with age, but younger adults can also develop the disease, particularly when tumors are driven by specific genetic alterations.
Fact: Most persistent coughs are not caused by cancer, but symptoms that continue despite appropriate treatment should not be ignored.
Fact: Outcomes depend on the type of lung cancer, its stage at diagnosis, and access to appropriate treatment.
"Lung cancer is often misconceived to be a non-curable disease. But with early detection and focused expert oncology care, most of these patients remain disease free and living a healthy life." says Dr. Faheem Abdulla, Thoracic Oncologist and Surgical Oncologist.
Not every case of lung cancer in never-smokers can be prevented because some tumors arise without an identifiable cause. However, reducing exposure to known risk factors may help lower the risk.
Evidence-based preventive measures include:
Avoid exposure to secondhand tobacco smoke.
Improve ventilation when using biomass fuels for cooking or heating.
Follow workplace safety measures when handling carcinogens such as asbestos or silica.
Consider testing homes for radon in regions where radon exposure is known to be a concern.
Avoid smoking and other tobacco products.
Seek medical evaluation for persistent respiratory symptoms instead of assuming they are due to allergies or a routine infection.
Attend regular health check-ups and discuss any persistent respiratory concerns with a healthcare professional.
While these measures cannot eliminate risk completely, they can reduce exposure to several established causes of lung cancer and support earlier diagnosis when symptoms develop.
Consider seeking medical evaluation if you experience:
A cough lasting longer than three to four weeks.
Coughing up blood.
Persistent or worsening breathlessness.
Chest pain that does not resolve.
Recurrent pneumonia or repeated chest infections.
Persistent hoarseness.
Unexplained weight loss.
Persistent fatigue without a clear cause.
These symptoms are far more commonly caused by conditions other than lung cancer. However, persistent or unexplained symptoms deserve proper medical assessment rather than self-diagnosis.
Public awareness campaigns have rightly emphasized the dangers of tobacco, and smoking prevention remains one of the most effective ways to reduce lung cancer worldwide.
At the same time, awareness must evolve to recognize another important reality: people who have never smoked can also develop lung cancer.
Reducing stigma, recognizing symptoms earlier, understanding established risk factors, and ensuring timely access to appropriate diagnostic testing may help improve outcomes for these patients.
As Dr. Anjali Singh reminds us, lung cancer should no longer be viewed exclusively as a smoker's disease. And as Dr. Vivek Gundappa notes, maintaining a high index of suspicion and referring patients promptly for advanced evaluation can make a meaningful difference.
This World Lung Cancer Day, the message is straightforward: never smoking lowers the risk of lung cancer, but it does not eliminate it. Persistent respiratory symptoms should never be ignored simply because someone has never smoked. Early evaluation can lead to earlier diagnosis, more treatment options, and better outcomes.
World Health Organization. "Lung Cancer." World Health Organization. Published April 16, 2026. Accessed August 1, 2026. https://www.who.int/news-room/fact-sheets/detail/lung-cancer
World Health Organization. "Household Air Pollution and Health." World Health Organization. Accessed August 1, 2026. https://www.who.int/news-room/fact-sheets/detail/household-air-pollution-and-health
World Health Organization. "Air Pollution." World Health Organization. Accessed August 1, 2026. https://www.who.int/health-topics/air-pollution
International Agency for Research on Cancer (IARC). Outdoor Air Pollution. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 109. Lyon, France: International Agency for Research on Cancer, 2016. https://publications.iarc.fr/538
Samet, Jonathan M., Eduardo Avila-Tang, Paolo Boffetta, et al. "Lung Cancer in Never Smokers: Clinical Epidemiology and Environmental Risk Factors." Clinical Cancer Research 15, no. 18 (2009): 5626-5645. https://doi.org/10.1158/1078-0432.CCR-09-0376
Sun, Shujie, Joan H. Schiller, and Adi F. Gazdar. "Lung Cancer in Never Smokers: A Different Disease." Nature Reviews Cancer 7, no. 10 (2007): 778-790. https://doi.org/10.1038/nrc2190
Couraud, Sébastien, Gérard Zalcman, Bernard Milleron, Fabrice Morin, and Pierre-Jean Souquet. "Lung Cancer in Never Smokers: A Review." European Respiratory Journal 45, no. 4 (2015): 1214-1217. https://doi.org/10.1183/09031936.00092314
Lindeman, Neal I., Philip T. Cagle, Dara L. Aisner, et al. "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology." Journal of Thoracic Oncology 13, no. 3 (2018): 323-358. https://doi.org/10.1016/j.jtho.2017.12.001
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer. Version current at time of publication. Plymouth Meeting, PA: National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
National Cancer Institute. "Non-Small Cell Lung Cancer Treatment (PDQ®)." National Cancer Institute. Accessed August 1, 2026. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
U.S. Preventive Services Task Force. Krist, Alex H., et al. "Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement." JAMA 325, no. 10 (2021): 962-970. https://doi.org/10.1001/jama.2021.1117
American Cancer Society. "Lung Cancer Screening Guidelines." American Cancer Society. Accessed August 1, 2026. https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/lung-cancer-screening-guidelines.html
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Lung Cancer Screening. Version current at time of publication. Plymouth Meeting, PA: National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf
U.S. Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2016. https://e-cigarettes.surgeongeneral.gov/
International Association for Research on Cancer (IARC). "Lung Cancer." International Agency for Research on Cancer. Accessed August 1, 2026. https://www.iarc.who.int/cancer-type/lung-cancer/